Year-long study shows people with mild Alzheimer’s can successfully monitor brain health from home, pointing toward faster research.
To understand whether a treatment is working, researchers need data. Lots of it. But collecting that data usually means asking people – many of them older adults living with cognitive decline – to travel repeatedly to specialist clinics, complete lengthy assessments and return months later to do it all again. The result is expensive studies built around occasional snapshots of a disease that changes every day.
So what if the answer isn’t collecting more people, but collecting better data?
That is one of the questions raised by a newly published study from Cumulus Neuroscience. The company’s year-long trial suggests that frequent brain health assessments carried out at home could capture the subtle day-to-day changes that clinic visits inevitably miss [1]. In research terms, that means stronger statistical power – the confidence that a study can detect whether a treatment is actually making a difference. Put simply, richer data from each participant could one day allow companies to run smaller, shorter and less costly Alzheimer’s trials.
The second surprise is perhaps even more human. Many participants living with mild Alzheimer’s disease dementia admitted they were not especially confident using the technology at first. Yet once they began, they completed virtually every session they started. Sometimes willingness matters more than confidence.
Published in Frontiers in Digital Health, the CNS-101 study followed 119 participants across seven clinical sites in the UK over 52 weeks. Fifty-nine participants were living with mild Alzheimer’s disease dementia, while 60 healthy older adults served as age-matched controls.
After a single training session in clinic, participants returned home with Cumulus’ NeuLogiq Platform, a wireless headset that records brain activity alongside a tablet featuring interactive cognitive exercises. Rather than visiting a clinic every few months, participants completed assessments from their own homes throughout the year.
The study was designed to answer a straightforward question: could people living with Alzheimer’s actually use the system consistently on their own? The answer appears to be yes. Participants with Alzheimer’s completed 99.7% of every assessment session they initiated and maintained a 77% adherence rate throughout the demanding year-long protocol. Healthy participants achieved an adherence rate of 88.8%. Those numbers matter because long-term participation is often one of the hardest parts of clinical research, particularly in older populations.
Dr Brian Murphy, co-founder and Chief Scientific Officer of Cumulus, said that the study represented an important milestone for both the NeuLogiq Platform and the broader initiative to introduce more sensitive, real-world measurements to Alzheimer’s disease. He highlighted that individuals living with mild dementia, rather than just healthy volunteers, were both capable and willing to use an EEG headset and complete cognitive tasks unsupervised in their own homes for an entire year, ultimately finishing nearly every session they started.
“That combination of high adherence and genuine patient acceptability in this population is an important foundation for designing trials that track disease progression more frequently and more precisely, while reducing the burden on patients and the cost and duration of studies,” he added.
Why do more frequent measurements matter? Think of trying to understand the weather by stepping outside just four times a year. You might know whether it’s winter or summer, but you’d miss the storms, the heatwaves and the gradual shifts in between. Alzheimer’s research has traditionally worked in much the same way.
Today’s standard cognitive assessments are usually carried out during scheduled clinic visits months apart. They remain valuable, but they capture isolated moments rather than the day-to-day reality of how cognition fluctuates. Stress, fatigue, travel and unfamiliar surroundings can also influence performance, making it harder to distinguish genuine disease progression from ordinary variation.
Collecting data more frequently – and from the comfort of home – helps fill in those gaps. Instead of relying on scattered snapshots, researchers begin building something closer to a time-lapse of how the brain changes over months. That richer picture doesn’t just improve scientific understanding; it could also make future trials more efficient by detecting meaningful changes earlier and with greater precision.
Professor James Rowe, Professor of Cognitive Neurology at the University of Cambridge and Principal Investigator of CNS-101, believes that the shift is overdue. He explained that the conventional tools used in Alzheimer’s trials were not originally designed to detect the subtle, day-to-day cognitive shifts that are crucial in the early stages of the disease, noting that the high cost and infrequency of clinic visits further restrict measurement capabilities.
However, Rowe highlighted that the study successfully demonstrates how regular, objective monitoring of brain activity and cognition can be transitioned to patients’ homes – even for those living with dementia – while maintaining high adherence and strong acceptability over the course of a year.
“Collecting data in a familiar environment, free of the stress and fatigue of lengthy clinic visits, is not only more comfortable for patients and families – it is a necessary step toward more sensitive, patient-friendly endpoints for the next generation of Alzheimer’s trials,” he added.
Perhaps the most revealing finding had little to do with software or sensors. Participants living with Alzheimer’s reported considerably less confidence using the technology than healthy volunteers, and some experienced minor setup challenges during their first sessions. Ordinarily, researchers might expect that uncertainty to translate into people giving up. Instead, the opposite happened.
Nearly every session that participants began was completed. That suggests the real innovation may extend beyond the hardware itself. By designing assessments that fit naturally into people’s routines and presenting cognitive exercises in a more approachable, game-like format, the platform appears to lower the psychological barriers that often discourage participation. It is an important reminder that successful digital health tools are the ones people actually continue using.
The study was not designed to determine whether the platform improves patient outcomes or measures treatment effectiveness. Its purpose was more foundational: to establish that collecting high-quality brain health data at home is both practical and acceptable for people living with mild Alzheimer’s disease. On that question, it delivered encouraging evidence.
As therapies for Alzheimer’s continue to emerge, the challenge is shifting from discovering potential treatments to evaluating them quickly enough and accurately enough to know which ones truly work.
Now, if collecting richer data from each participant strengthens statistical power, future Alzheimer’s trials may no longer need to rely on ever-larger patient populations or years of follow-up to reach meaningful conclusions. Better measurements could become just as valuable as bigger studies.
Moreover, if people living with dementia are willing to engage with thoughtfully designed digital tools, even when they don’t feel completely confident using them, it suggests something equally important: patients are not passive participants waiting for care to happen to them. Given the right experience, many are ready to take an active role in generating the data that could accelerate the next generation of treatments.
For longevity, those ideas matter because they point in the same direction. Progress may come not only from breakthrough drugs, but from rethinking how we measure aging itself – more often, more naturally and closer to where life actually happens: at home.
Photograph courtesy of Cumulus Neuroscience
[1] https://www.cumulusneuro.com/news/2026-06-30-cns-101-publication
